MedTrace Logo

BlueWind Reprieve System for the Treatment of PNP

NCT02209896 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2018-04-11

No results posted yet for this study

Summary

The BlueWind Reprieve system is a neurostimulator consisting of an Implant and external components.

The system is intended for home care use. The chronic pain treatment is achieved by an electrical stimulation of peripheral nerve fibers. The stimulation is set so that it generates paresthesia in the stimulated area (e.g. foot), reducing the pain sensation and improving the quality of life for the patient.

Conditions

  • Peripheral Neuropathic Pain

Interventions

DEVICE

The Reprieve system

BlueWind Medical neurostimulator for the treatment of neuropathic pain

Sponsors & Collaborators

  • BlueWind Medical

    lead INDUSTRY

Principal Investigators

  • Ron Dabby, MD · Wolfson Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02209896 on ClinicalTrials.gov